DK0702085T3 - Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus - Google Patents

Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus

Info

Publication number
DK0702085T3
DK0702085T3 DK95201936T DK95201936T DK0702085T3 DK 0702085 T3 DK0702085 T3 DK 0702085T3 DK 95201936 T DK95201936 T DK 95201936T DK 95201936 T DK95201936 T DK 95201936T DK 0702085 T3 DK0702085 T3 DK 0702085T3
Authority
DK
Denmark
Prior art keywords
stranded rna
rna virus
segmented negative
recombinant infectious
infectious non
Prior art date
Application number
DK95201936T
Other languages
English (en)
Other versions
DK0702085T4 (da
Inventor
Karl Klaus Conzelmann
Original Assignee
Conzelmann Karl Klaus Prof Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8217048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0702085(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conzelmann Karl Klaus Prof Dr filed Critical Conzelmann Karl Klaus Prof Dr
Application granted granted Critical
Publication of DK0702085T3 publication Critical patent/DK0702085T3/da
Publication of DK0702085T4 publication Critical patent/DK0702085T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK95201936.2T 1994-07-18 1995-07-14 Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus DK0702085T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94202089 1994-07-18

Publications (2)

Publication Number Publication Date
DK0702085T3 true DK0702085T3 (da) 2004-04-19
DK0702085T4 DK0702085T4 (da) 2010-04-06

Family

ID=8217048

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95201936.2T DK0702085T4 (da) 1994-07-18 1995-07-14 Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus

Country Status (10)

Country Link
US (1) US6033886A (da)
EP (2) EP1394259A3 (da)
JP (2) JP3816126B2 (da)
CN (2) CN100447247C (da)
AT (1) ATE257175T1 (da)
CA (1) CA2154023C (da)
DE (1) DE69532369T3 (da)
DK (1) DK0702085T4 (da)
ES (1) ES2210273T5 (da)
PT (1) PT702085E (da)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) † 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
DE69510207T3 (de) 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
EP0864645B9 (en) 1995-10-31 2006-03-22 Dnavec Research Inc. Negative-strand rna virus vector having autonomously replicating activity
EP0863202B1 (en) * 1995-11-01 2010-06-09 Dnavec Research Inc. Recombinant sendai virus
EP2112220A3 (en) 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
AU4427897A (en) * 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
ES2289782T3 (es) * 1997-05-07 2008-02-01 The Cleveland Clinic Foundation Clon infeccioso para el virus parainfluenza de tipo 3 humano.
AU2007203671B2 (en) * 1997-05-23 2011-09-01 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
AU7797798A (en) * 1997-05-23 1998-12-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7208161B1 (en) 1997-05-23 2007-04-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
PT1012244E (pt) * 1997-07-11 2007-08-21 Univ Yale ''rabdovírus com revestimentos remanipulados''
US7081243B1 (en) 1997-07-11 2006-07-25 Yale University Rhabdoviruses with reengineered coats
US6830748B1 (en) * 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
DK1098961T3 (da) 1998-06-12 2008-05-26 Andrej Y Dr Egorov Gensplejsede svækkede vira, der inducerer interferon
US6573079B1 (en) 1998-06-12 2003-06-03 Mount Sinai School Of Medicine Of New York University Methods and interferon deficient substrates for the propagation of viruses
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US7618797B2 (en) 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
CA2361421A1 (en) * 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
EP1035205A1 (en) * 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
EP1287152B1 (en) 1999-07-09 2008-12-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Human-bovine chimeric respiratory syncytial virus vaccines
US7820182B2 (en) * 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
JP4791651B2 (ja) * 2000-05-18 2011-10-12 株式会社ディナベック研究所 外来遺伝子導入用パラミクソウイルスベクター
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
US6664066B2 (en) 2000-06-23 2003-12-16 Wyeth Holdings Corporation Modified Morbillivirus V proteins
ATE437223T1 (de) 2000-06-23 2009-08-15 Intervet Int Bv Attenuiertes bovines respiratorisches syncytialvirus
KR20090006239A (ko) * 2000-06-23 2009-01-14 와이어쓰 홀딩스 코포레이션 ｃＤＮＡ로 부터 개 홍역 바이러스의 구출
AU2001290273A1 (en) * 2000-10-06 2002-04-22 Dnavec Research Inc. Paramyxovirus vector for transferring foreign gene into skeletal muscle
JP2002142770A (ja) * 2000-11-08 2002-05-21 Dnavec Research Inc 循環系への遺伝子送達用パラミクソウイルスベクター
WO2002098457A2 (en) * 2001-01-17 2002-12-12 Thomas Jefferson University Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
NZ527221A (en) 2001-01-19 2006-09-29 Vironovative B A negative-sense single stranded RNA virus causing respiratory tract illness in susceptible mammals
US20030232061A1 (en) * 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
JP2004537305A (ja) * 2001-07-11 2004-12-16 ユニバーシティー オブ マイアミ 腫瘍細胞の処置のための組換えｖｓｖ
CA2454397A1 (en) * 2001-07-20 2003-06-05 The University Of Georgia Research Foundation, Inc. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the cns
JP4553588B2 (ja) 2002-02-21 2010-09-29 メディミューン，エルエルシー メタニューモウイルス（ｍｅｔａｐｎｅｕｍｏｖｉｒｕｓ）株と、ワクチン製剤でのおよび抗原配列発現用ベクターとしてのその使用
WO2003091401A2 (en) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
FR2839453B1 (fr) 2002-05-07 2007-05-11 Agronomique Inst Nat Rech Utilisation de novirhabdovirus modifies pour l'obtention de vaccins
US20050260601A1 (en) * 2002-09-09 2005-11-24 Whitt Michael A Recombinant mutants of rhabdovirus and methods of use thereof
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
JP2007525178A (ja) 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
WO2004112831A2 (en) 2003-05-28 2004-12-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
EP1633860A2 (en) * 2003-06-09 2006-03-15 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ES2345492T3 (es) * 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
HUE032898T2 (hu) 2003-12-24 2017-11-28 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Volksgezondheid Welzijn En Sport Légúti óriássejtes vírus transz komplementált genomi hiányossággal
CA2561245C (en) 2004-04-09 2013-06-18 Wyeth Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
WO2005116260A2 (en) 2004-05-25 2005-12-08 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ES2694123T3 (es) 2004-06-01 2018-12-18 Icahn School Of Medicine At Mount Sinai Virus de la gripe porcina modificado por ingeniería genética y usos de los mismos
JP2006121948A (ja) * 2004-10-27 2006-05-18 Kyoritsu Seiyaku Kk 組換えウイルス
CN101056646A (zh) 2004-11-12 2007-10-17 拜耳先灵医药股份有限公司 重组新城疫病毒
US7968101B2 (en) 2004-11-19 2011-06-28 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
KR20080025171A (ko) 2005-06-21 2008-03-19 메드이뮨 백신즈 인코포레이티드 이종성 프로테아제를 발현시키기 위한 방법 및 조성물
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
AU2006304268B2 (en) 2005-10-14 2011-09-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus vector systems and compositions and methods thereof
PT2251034T (pt) 2005-12-02 2018-05-22 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
US9254318B2 (en) 2006-03-31 2016-02-09 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
DK2016194T3 (da) 2006-04-19 2015-06-15 Medimmune Llc Fremgangsmåder og sammensætninger til ekspression af viralt negativ-sense-rna i hundeceller
AU2007240797B2 (en) * 2006-04-20 2013-05-23 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
EP2049662A4 (en) 2006-07-21 2009-12-30 Medimmune Llc METHODS AND COMPOSITIONS FOR INCREASING REPLICATION CAPACITY OF A FLU VIRUS
CA2659267C (en) 2006-08-09 2016-12-13 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US7785874B2 (en) * 2007-01-11 2010-08-31 The Salk Institute For Biological Studies Compositions and methods for monosynaptic transport
JP5666905B2 (ja) 2007-06-18 2015-02-12 メディミューン，エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザｂウイルス
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
US20090186050A1 (en) * 2007-11-16 2009-07-23 Fouchier Ron A M Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains
CA2710350A1 (en) * 2007-12-21 2009-07-02 Wyeth Llc Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
SG192501A1 (en) 2008-07-11 2013-08-30 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
WO2010093537A2 (en) 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
JP5845180B2 (ja) 2009-07-30 2016-01-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルス及びそれらの使用
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
JP6087908B2 (ja) 2011-06-08 2017-03-08 ジョシ ヴィシュワスＪＯＳＨＩ Ｖｉｓｈｗａｓ 組換えタンパク質および組換えウイルスを作製するための単純な２プラスミド哺乳動物発現系
EP2758075B1 (en) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
KR102012109B1 (ko) 2012-05-17 2019-08-19 조에티스 엘엘씨 이유 전 돼지 생식기 호흡기 증후군(prrs) 바이러스에 대한 효과적인 백신접종
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
BR112015021414B1 (pt) 2013-03-14 2020-11-10 Icahn School Of Medicine At Mount Sinai vírus da doença newcastle e seus usos
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105189756B (zh) 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3261664A1 (en) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalent swine influenza virus vaccine
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
CN104962580B (zh) * 2015-06-30 2018-04-27 浙江大学 一种重组植物弹状病毒载体及其构建方法
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US10973903B2 (en) 2015-08-20 2021-04-13 University Of Rochester NS1 truncated virus for the development of canine influenza vaccines
WO2017031404A1 (en) 2015-08-20 2017-02-23 University Of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
US10548966B2 (en) 2015-08-20 2020-02-04 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
US11235050B2 (en) 2015-10-29 2022-02-01 Emory University Chimeric RSV, immunogenic compositions, and methods of use
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
CA3026256A1 (en) 2016-06-03 2017-12-07 University Of Rochester Equine influenza virus live-attenuated vaccines
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3047294A1 (en) 2016-12-14 2018-06-21 Zoetis Services Llc Effective vaccination against european strains of porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
MX2020008927A (es) 2018-02-27 2021-01-08 Univ Rochester Vacuna contra la influenza atenuada viva multivalente para la prevencion y el control del virus de la influenza equina (eiv) en caballos.
CN109136200B (zh) * 2018-09-20 2022-02-18 中国水产科学研究院黑龙江水产研究所 一种重组传染性造血器官坏死病毒及其构建方法与应用
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
JP2022527235A (ja) 2019-01-23 2022-06-01 義裕 河岡 インフルエンザウイルスにおける付加的遺伝子に遺伝的安定性を付与する突然変異
JP2022522112A (ja) 2019-02-08 2022-04-14 ウィスコンシン アルムニ リサーチ ファンデイション ヒト化細胞系
MX2021010343A (es) 2019-02-27 2022-01-18 Univ Rochester Vacuna para la influenza multivalente con virus vivo atenuado para la prevencion y el control del virus de la influenza equina (eiv) en caballos.
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
JP2022551805A (ja) 2019-08-27 2022-12-14 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
CN113234692B (zh) * 2021-05-11 2022-02-22 华中农业大学 一种包含狂犬病毒糖蛋白的感染性克隆及应用
WO2023227758A1 (en) 2022-05-25 2023-11-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccine with reduced anti-vector antigenicity
CN114859064B (zh) * 2022-06-07 2023-04-25 中国农业科学院兰州兽医研究所 一种牛流行热病毒蛋白复合物及在牛流行热病毒自然感染抗体检测中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
ZA937164B (en) * 1992-09-28 1994-05-23 Commw Scient Ind Res Org Delivery system

Also Published As

Publication number Publication date
JP2006136340A (ja) 2006-06-01
CA2154023A1 (en) 1996-01-19
DK0702085T4 (da) 2010-04-06
ATE257175T1 (de) 2004-01-15
CN1121959A (zh) 1996-05-08
EP0702085A1 (en) 1996-03-20
EP0702085B9 (en) 2005-03-16
PT702085E (pt) 2004-04-30
ES2210273T3 (es) 2004-07-01
DE69532369D1 (de) 2004-02-05
ES2210273T5 (es) 2010-03-29
EP0702085B2 (en) 2010-01-13
DE69532369T2 (de) 2004-12-09
CN100447247C (zh) 2008-12-31
JPH08168381A (ja) 1996-07-02
DE69532369T3 (de) 2010-11-04
JP3816126B2 (ja) 2006-08-30
US6033886A (en) 2000-03-07
EP1394259A2 (en) 2004-03-03
EP1394259A3 (en) 2004-04-14
JP4704232B2 (ja) 2011-06-15
EP0702085B1 (en) 2004-01-02
CN1912112A (zh) 2007-02-14
CA2154023C (en) 2007-04-10

Similar Documents

Publication Publication Date Title
DK0702085T3 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
ATE397070T1 (de) Klonierte genome von infektiösen hepatitis c viren und deren verwendungen
NO874750L (no) Bestemte dna-sekvenser avledet fra et papillomavirusgenom, deres bruk i in vitro diagnostikk og produksjon av antigene preparater.
ATE329616T1 (de) Virale nukleotidsequenz vr-2332 und nutzungsverfahren
DE69515028D1 (de) Die hocheffiziente herstellung und isolierung von viruspartikeln
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
ATE60800T1 (de) Klonierte dns-sequenzen, hybridisierbar mit genom-rns vom ''lymphadenopathy-associated virus (lav)''.
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
YU37502A (sh) Infektivni klonovi
ATE393234T1 (de) Adenovirale vektoren und eine methode zur reduktion von homologer rekombination
ATE399210T1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
DE60331758D1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
ATE362538T1 (de) Klonierte genome von infektiösen hepatitis c viren genotyp 2a und deren verwendungen
DE60040219D1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
DE69125066D1 (de) cDNS-Sequenz und Detektion des Hepatitis C-Virus
ATE346087T1 (de) Hepatitis e-virus aus dem schwein und dessen verwendungen
WO1999057284A3 (en) Attenuated influenza viruses
WO2000075352A3 (en) Hcv/bvdv chimeric genomes and uses thereof
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS
PT1254663E (pt) Agente antiviral
WO2001011065A3 (en) Hepatitis a virus clones adapted for growth in agmk cells
TH62970A (th) วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)